메뉴 건너뛰기




Volumn 42, Issue 2, 2015, Pages 99-108

Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy

Author keywords

Bombesin; Gastrin releasing peptide; Prostate cancer; RGD; RM2

Indexed keywords

ARGINYLGLYCYLASPARTICGLUTAMIC ACID 6 AMINO HEXANOIC ACID RM2 TETRAXETAN INDIUM IN 111; ARGINYLGLYCYLASPARTICGLUTAMIC ACID 6 AMINO HEXANOIC ACID RM2 TETRAXETAN LUTETIUM LU 177; GASTRIN RELEASING PEPTIDE RECEPTOR; INDIUM 111; LUTETIUM 177; RADIOPHARMACEUTICAL AGENT; TETRAXETAN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; ARGINYL-GLYCYL-ASPARTIC ACID; BOMBESIN; BOMBESIN RECEPTOR; COPPER; OLIGOPEPTIDE; SINGLE HETEROCYCLIC RINGS;

EID: 84921293040     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.10.002     Document Type: Article
Times cited : (33)

References (75)
  • 2
    • 84894099296 scopus 로고    scopus 로고
    • The economic burden of skeletal-related events among elderly men with metastatic prostate cancer
    • Jayasekera J., Onukwugha E., Bikov K., Mullins C.D., Seal B., Hussain A. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer. PharmacoEconomics 2014, 32:173-191.
    • (2014) PharmacoEconomics , vol.32 , pp. 173-191
    • Jayasekera, J.1    Onukwugha, E.2    Bikov, K.3    Mullins, C.D.4    Seal, B.5    Hussain, A.6
  • 3
    • 84899482355 scopus 로고    scopus 로고
    • Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer
    • Yong C., Onukwugha E., Mullins C.D. Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer. Curr Opin Oncol 2014, 26:274-283.
    • (2014) Curr Opin Oncol , vol.26 , pp. 274-283
    • Yong, C.1    Onukwugha, E.2    Mullins, C.D.3
  • 4
    • 66149161780 scopus 로고    scopus 로고
    • Castration-resistant prostate cancer: locking up the molecular escape routes
    • Attar R.M., Takimoto C.H., Gottardis M.M. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 2009, 15:3251-3255.
    • (2009) Clin Cancer Res , vol.15 , pp. 3251-3255
    • Attar, R.M.1    Takimoto, C.H.2    Gottardis, M.M.3
  • 5
    • 60149089419 scopus 로고    scopus 로고
    • Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nature clinical practice
    • Harris W.P., Mostaghel E.A., Nelson P.S., Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nature clinical practice. Urology 2009, 6:76-85.
    • (2009) Urology , vol.6 , pp. 76-85
    • Harris, W.P.1    Mostaghel, E.A.2    Nelson, P.S.3    Montgomery, B.4
  • 6
    • 79956345344 scopus 로고    scopus 로고
    • Screening for prostate cancer with PSA testing: current status and future directions
    • [63]
    • Croswell J.M., Kramer B.S., Crawford E.D. Screening for prostate cancer with PSA testing: current status and future directions. Oncology (Williston Park) 2011, 25:452-460. [63].
    • (2011) Oncology (Williston Park) , vol.25 , pp. 452-460
    • Croswell, J.M.1    Kramer, B.S.2    Crawford, E.D.3
  • 7
    • 84861847420 scopus 로고    scopus 로고
    • Prostate-cancer mortality after PSA screening
    • D'Amico A.V. Prostate-cancer mortality after PSA screening. N Engl J Med 2012, 366:2229.
    • (2012) N Engl J Med , vol.366 , pp. 2229
    • D'Amico, A.V.1
  • 8
    • 79960444176 scopus 로고    scopus 로고
    • Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?
    • Duffy M.J. Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?. Ann Clin Biochem 2011, 48:310-316.
    • (2011) Ann Clin Biochem , vol.48 , pp. 310-316
    • Duffy, M.J.1
  • 9
    • 84896466669 scopus 로고    scopus 로고
    • Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence
    • Hayes J.H., Barry M.J. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA 2014, 311:1143-1149.
    • (2014) JAMA , vol.311 , pp. 1143-1149
    • Hayes, J.H.1    Barry, M.J.2
  • 10
    • 84871908883 scopus 로고    scopus 로고
    • The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States
    • Howrey B.T., Kuo Y.F., Lin Y.L., Goodwin J.S. The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. J Gerontol A: Biol Med Sci 2013, 68:56-61.
    • (2013) J Gerontol A: Biol Med Sci , vol.68 , pp. 56-61
    • Howrey, B.T.1    Kuo, Y.F.2    Lin, Y.L.3    Goodwin, J.S.4
  • 11
    • 84898753498 scopus 로고    scopus 로고
    • Further evidence that prostate-specific antigen screening reduces prostate cancer mortality
    • Stampfer M.J., Jahn J.L., Gann P.H. Further evidence that prostate-specific antigen screening reduces prostate cancer mortality. J Natl Cancer Inst 2014, 106:dju026.
    • (2014) J Natl Cancer Inst , vol.106
    • Stampfer, M.J.1    Jahn, J.L.2    Gann, P.H.3
  • 12
    • 84905912396 scopus 로고    scopus 로고
    • A different method of evaluation of the ERSPC Trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality
    • Zappa M., Puliti D., Hugosson J., Schroder F.H., van Leeuwen P.J., Kranse R., et al. A different method of evaluation of the ERSPC Trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality. Eur Urol 2014, 66:401-403.
    • (2014) Eur Urol , vol.66 , pp. 401-403
    • Zappa, M.1    Puliti, D.2    Hugosson, J.3    Schroder, F.H.4    van Leeuwen, P.J.5    Kranse, R.6
  • 13
    • 84874543674 scopus 로고    scopus 로고
    • Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases
    • Nilsson S., Franzen L., Parker C., Tyrrell C., Blom R., Tennvall J., et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer 2013, 11:20-26.
    • (2013) Clin Genitourin Cancer , vol.11 , pp. 20-26
    • Nilsson, S.1    Franzen, L.2    Parker, C.3    Tyrrell, C.4    Blom, R.5    Tennvall, J.6
  • 14
    • 0042854927 scopus 로고    scopus 로고
    • Peptide receptors as molecular targets for cancer diagnosis and therapy
    • Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003, 24:389-427.
    • (2003) Endocr Rev , vol.24 , pp. 389-427
    • Reubi, J.C.1
  • 15
    • 57349195981 scopus 로고    scopus 로고
    • Peptide-based probes for cancer imaging
    • Reubi J.C., Maecke H.R. Peptide-based probes for cancer imaging. J Nucl Med 2008, 49:1735-1738.
    • (2008) J Nucl Med , vol.49 , pp. 1735-1738
    • Reubi, J.C.1    Maecke, H.R.2
  • 18
    • 34547176710 scopus 로고    scopus 로고
    • 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties
    • 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties. Bioconjug Chem 2007, 18:1110-1117.
    • (2007) Bioconjug Chem , vol.18 , pp. 1110-1117
    • Parry, J.J.1    Kelly, T.S.2    Andrews, R.3    Rogers, B.E.4
  • 19
    • 84876950056 scopus 로고    scopus 로고
    • Near-infrared fluorescence imaging of gastrin releasing peptide receptor targeting in prostate cancer lymph node metastases
    • Cai Q.Y., Yu P., Besch-Williford C., Smith C.J., Sieckman G.L., Hoffman T.J., et al. Near-infrared fluorescence imaging of gastrin releasing peptide receptor targeting in prostate cancer lymph node metastases. Prostate 2013, 73:842-854.
    • (2013) Prostate , vol.73 , pp. 842-854
    • Cai, Q.Y.1    Yu, P.2    Besch-Williford, C.3    Smith, C.J.4    Sieckman, G.L.5    Hoffman, T.J.6
  • 22
    • 0033104343 scopus 로고    scopus 로고
    • Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation
    • Markwalder R., Reubi J.C. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999, 59:1152-1159.
    • (1999) Cancer Res , vol.59 , pp. 1152-1159
    • Markwalder, R.1    Reubi, J.C.2
  • 23
    • 12144279487 scopus 로고    scopus 로고
    • Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study
    • Nock B.A., Nikolopoulou A., Galanis A., Cordopatis P., Waser B., Reubi J.C., et al. Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem 2005, 48:100-110.
    • (2005) J Med Chem , vol.48 , pp. 100-110
    • Nock, B.A.1    Nikolopoulou, A.2    Galanis, A.3    Cordopatis, P.4    Waser, B.5    Reubi, J.C.6
  • 24
    • 84862577703 scopus 로고    scopus 로고
    • Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates
    • Patil V., Gada K., Panwar R., Varvarigou A., Majewski S., Weisenberger A., et al. Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates. Eur J Nucl Med Mol Imaging 2012, 39:824-839.
    • (2012) Eur J Nucl Med Mol Imaging , vol.39 , pp. 824-839
    • Patil, V.1    Gada, K.2    Panwar, R.3    Varvarigou, A.4    Majewski, S.5    Weisenberger, A.6
  • 25
    • 34547630542 scopus 로고    scopus 로고
    • 64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues
    • 64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci U S A 2007, 104:12462-12467.
    • (2007) Proc Natl Acad Sci U S A , vol.104 , pp. 12462-12467
    • Prasanphanich, A.F.1    Nanda, P.K.2    Rold, T.L.3    Ma, L.4    Lewis, M.R.5    Garrison, J.C.6
  • 26
    • 79958060431 scopus 로고    scopus 로고
    • Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts
    • Schroeder R.P., van Weerden W.M., Krenning E.P., Bangma C.H., Berndsen S., Grievink-de Ligt C.H., et al. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts. Eur J Nucl Med Mol Imaging 2011, 38:1257-1266.
    • (2011) Eur J Nucl Med Mol Imaging , vol.38 , pp. 1257-1266
    • Schroeder, R.P.1    van Weerden, W.M.2    Krenning, E.P.3    Bangma, C.H.4    Berndsen, S.5    Grievink-de Ligt, C.H.6
  • 28
    • 0043267475 scopus 로고    scopus 로고
    • Radiochemical investigations of gastrin-releasing peptide receptor-specific [(99m)Tc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where Dpr=2,3-diaminopropionic acid and X=H2O or P(CH2OH)3
    • Smith C.J., Sieckman G.L., Owen N.K., Hayes D.L., Mazuru D.G., Kannan R., et al. Radiochemical investigations of gastrin-releasing peptide receptor-specific [(99m)Tc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where Dpr=2,3-diaminopropionic acid and X=H2O or P(CH2OH)3. Cancer Res 2003, 63:4082-4088.
    • (2003) Cancer Res , vol.63 , pp. 4082-4088
    • Smith, C.J.1    Sieckman, G.L.2    Owen, N.K.3    Hayes, D.L.4    Mazuru, D.G.5    Kannan, R.6
  • 30
    • 33646050623 scopus 로고    scopus 로고
    • 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma
    • 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol 2006, 33:371-380.
    • (2006) Nucl Med Biol , vol.33 , pp. 371-380
    • Yang, Y.S.1    Zhang, X.2    Xiong, Z.3    Chen, X.4
  • 31
    • 84878863911 scopus 로고    scopus 로고
    • An update of radiolabeled bombesin analogs for gastrin-releasing peptide receptor targeting
    • Yu Z., Ananias H.J., Carlucci G., Hoving H.D., Helfrich W., Dierckx R.A., et al. An update of radiolabeled bombesin analogs for gastrin-releasing peptide receptor targeting. Curr Pharm Des 2013, 19:3329-3341.
    • (2013) Curr Pharm Des , vol.19 , pp. 3329-3341
    • Yu, Z.1    Ananias, H.J.2    Carlucci, G.3    Hoving, H.D.4    Helfrich, W.5    Dierckx, R.A.6
  • 32
    • 83755170780 scopus 로고    scopus 로고
    • Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors
    • Abiraj K., Mansi R., Tamma M.L., Fani M., Forrer F., Nicolas G., et al. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med 2011, 52:1970-1978.
    • (2011) J Nucl Med , vol.52 , pp. 1970-1978
    • Abiraj, K.1    Mansi, R.2    Tamma, M.L.3    Fani, M.4    Forrer, F.5    Nicolas, G.6
  • 33
    • 0023637601 scopus 로고
    • New perspectives in cell adhesion: RGD and integrins
    • Ruoslahti E., Pierschbacher M.D. New perspectives in cell adhesion: RGD and integrins. Science 1987, 238:491-497.
    • (1987) Science , vol.238 , pp. 491-497
    • Ruoslahti, E.1    Pierschbacher, M.D.2
  • 34
    • 0033119722 scopus 로고    scopus 로고
    • RGD-recognizing integrins mediate interactions of human prostate carcinoma cells with endothelial cells in vitro
    • Romanov V.I., Goligorsky M.S. RGD-recognizing integrins mediate interactions of human prostate carcinoma cells with endothelial cells in vitro. Prostate 1999, 39:108-118.
    • (1999) Prostate , vol.39 , pp. 108-118
    • Romanov, V.I.1    Goligorsky, M.S.2
  • 35
    • 84872019911 scopus 로고    scopus 로고
    • RGD-binding integrins in prostate cancer: expression patterns and therapeutic prospects against bone metastasis
    • Sutherland M., Gordon A., Shnyder S.D., Patterson L.H., Sheldrake H.M. RGD-binding integrins in prostate cancer: expression patterns and therapeutic prospects against bone metastasis. Cancers 2012, 4:1106-1145.
    • (2012) Cancers , vol.4 , pp. 1106-1145
    • Sutherland, M.1    Gordon, A.2    Shnyder, S.D.3    Patterson, L.H.4    Sheldrake, H.M.5
  • 36
    • 73349138610 scopus 로고    scopus 로고
    • 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression
    • 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression. J Nucl Med 2009, 50:2017-2024.
    • (2009) J Nucl Med , vol.50 , pp. 2017-2024
    • Maddalena, M.E.1    Fox, J.2    Chen, J.3    Feng, W.4    Cagnolini, A.5    Linder, K.E.6
  • 37
    • 65249138736 scopus 로고    scopus 로고
    • Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers
    • Shi J., Kim Y.S., Zhai S., Liu Z., Chen X., Liu S. Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. Bioconjug Chem 2009, 20:750-759.
    • (2009) Bioconjug Chem , vol.20 , pp. 750-759
    • Shi, J.1    Kim, Y.S.2    Zhai, S.3    Liu, Z.4    Chen, X.5    Liu, S.6
  • 38
    • 33750420717 scopus 로고    scopus 로고
    • Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging
    • Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharm 2006, 3:472-487.
    • (2006) Mol Pharm , vol.3 , pp. 472-487
    • Liu, S.1
  • 39
    • 67651122837 scopus 로고    scopus 로고
    • Ligands for mapping alphavbeta3-integrin expression in vivo
    • Schottelius M., Laufer B., Kessler H., Wester H.J. Ligands for mapping alphavbeta3-integrin expression in vivo. Acc Chem Res 2009, 42:969-980.
    • (2009) Acc Chem Res , vol.42 , pp. 969-980
    • Schottelius, M.1    Laufer, B.2    Kessler, H.3    Wester, H.J.4
  • 42
    • 27944457471 scopus 로고    scopus 로고
    • MicroPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide
    • Wu Y., Zhang X., Xiong Z., Cheng Z., Fisher D.R., Liu S., et al. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med 2005, 46:1707-1718.
    • (2005) J Nucl Med , vol.46 , pp. 1707-1718
    • Wu, Y.1    Zhang, X.2    Xiong, Z.3    Cheng, Z.4    Fisher, D.R.5    Liu, S.6
  • 43
    • 33845697526 scopus 로고    scopus 로고
    • Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide
    • Dijkgraaf I., Kruijtzer J.A., Frielink C., Corstens F.H., Oyen W.J., Liskamp R.M., et al. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. Int J Cancer 2007, 120:605-610.
    • (2007) Int J Cancer , vol.120 , pp. 605-610
    • Dijkgraaf, I.1    Kruijtzer, J.A.2    Frielink, C.3    Corstens, F.H.4    Oyen, W.J.5    Liskamp, R.M.6
  • 44
    • 34447336118 scopus 로고    scopus 로고
    • (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression
    • Li Z.B., Cai W., Cao Q., Chen K., Wu Z., He L., et al. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med 2007, 48:1162-1171.
    • (2007) J Nucl Med , vol.48 , pp. 1162-1171
    • Li, Z.B.1    Cai, W.2    Cao, Q.3    Chen, K.4    Wu, Z.5    He, L.6
  • 50
    • 84892992101 scopus 로고    scopus 로고
    • A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] alphavbeta3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors
    • Durkan K., Jiang Z., Rold T.L., Sieckman G.L., Hoffman T.J., Bandari R.P., et al. A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] alphavbeta3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors. Nucl Med Biol 2014, 41:133-139.
    • (2014) Nucl Med Biol , vol.41 , pp. 133-139
    • Durkan, K.1    Jiang, Z.2    Rold, T.L.3    Sieckman, G.L.4    Hoffman, T.J.5    Bandari, R.P.6
  • 51
    • 66149176919 scopus 로고    scopus 로고
    • (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer
    • Liu Z., Yan Y., Liu S., Wang F., Chen X. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjug Chem 2009, 20:1016-1025.
    • (2009) Bioconjug Chem , vol.20 , pp. 1016-1025
    • Liu, Z.1    Yan, Y.2    Liu, S.3    Wang, F.4    Chen, X.5
  • 52
    • 67650093751 scopus 로고    scopus 로고
    • Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer
    • Liu Z., Li Z.B., Cao Q., Liu S., Wang F., Chen X. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer. J Nucl Med 2009, 50:1168-1177.
    • (2009) J Nucl Med , vol.50 , pp. 1168-1177
    • Liu, Z.1    Li, Z.B.2    Cao, Q.3    Liu, S.4    Wang, F.5    Chen, X.6
  • 54
    • 68949212307 scopus 로고    scopus 로고
    • (68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging
    • Liu Z., Niu G., Wang F., Chen X. (68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging 2009, 36:1483-1494.
    • (2009) Eur J Nucl Med Mol Imaging , vol.36 , pp. 1483-1494
    • Liu, Z.1    Niu, G.2    Wang, F.3    Chen, X.4
  • 55
    • 78649325858 scopus 로고    scopus 로고
    • Target-specific delivery of peptide-based probes for PET imaging
    • Chen K., Conti P.S. Target-specific delivery of peptide-based probes for PET imaging. Adv Drug Deliv Rev 2010, 62:1005-1022.
    • (2010) Adv Drug Deliv Rev , vol.62 , pp. 1005-1022
    • Chen, K.1    Conti, P.S.2
  • 57
    • 84877131430 scopus 로고    scopus 로고
    • Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin
    • Dumont R.A., Tamma M., Braun F., Borkowski S., Reubi J.C., Maecke H., et al. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin. J Nucl Med 2013, 54:762-769.
    • (2013) J Nucl Med , vol.54 , pp. 762-769
    • Dumont, R.A.1    Tamma, M.2    Braun, F.3    Borkowski, S.4    Reubi, J.C.5    Maecke, H.6
  • 58
    • 0035988207 scopus 로고    scopus 로고
    • Pm-149 DOTA bombesin analogs for potential radiotherapy. in vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-betaAla-BBN(7-14)NH(2)
    • Hu F., Cutler C.S., Hoffman T., Sieckman G., Volkert W.A., Jurisson S.S. Pm-149 DOTA bombesin analogs for potential radiotherapy. in vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-betaAla-BBN(7-14)NH(2). Nucl Med Biol 2002, 29:423-430.
    • (2002) Nucl Med Biol , vol.29 , pp. 423-430
    • Hu, F.1    Cutler, C.S.2    Hoffman, T.3    Sieckman, G.4    Volkert, W.A.5    Jurisson, S.S.6
  • 59
    • 33744812175 scopus 로고    scopus 로고
    • Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice
    • Johnson C.V., Shelton T., Smith C.J., Ma L., Perry M.C., Volkert W.A., et al. Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. Cancer Biother Radiopharm 2006, 21:155-166.
    • (2006) Cancer Biother Radiopharm , vol.21 , pp. 155-166
    • Johnson, C.V.1    Shelton, T.2    Smith, C.J.3    Ma, L.4    Perry, M.C.5    Volkert, W.A.6
  • 61
    • 0037291708 scopus 로고    scopus 로고
    • 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells
    • 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. Nucl Med Biol 2003, 30:101-109.
    • (2003) Nucl Med Biol , vol.30 , pp. 101-109
    • Smith, C.J.1    Gali, H.2    Sieckman, G.L.3    Hayes, D.L.4    Owen, N.K.5    Mazuru, D.G.6
  • 62
    • 4644360336 scopus 로고    scopus 로고
    • Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors
    • Zhang H., Chen J., Waldherr C., Hinni K., Waser B., Reubi J.C., et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 2004, 64:6707-6715.
    • (2004) Cancer Res , vol.64 , pp. 6707-6715
    • Zhang, H.1    Chen, J.2    Waldherr, C.3    Hinni, K.4    Waser, B.5    Reubi, J.C.6
  • 65
    • 34548119893 scopus 로고    scopus 로고
    • DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours
    • Zhang H., Schuhmacher J., Waser B., Wild D., Eisenhut M., Reubi J.C., et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging 2007, 34:1198-1208.
    • (2007) Eur J Nucl Med Mol Imaging , vol.34 , pp. 1198-1208
    • Zhang, H.1    Schuhmacher, J.2    Waser, B.3    Wild, D.4    Eisenhut, M.5    Reubi, J.C.6
  • 68
    • 0034184839 scopus 로고    scopus 로고
    • Labeling and in vivo evaluation of novel copper(II) dioxotetraazamacrocyclic complexes
    • Cutler C.S., Wuest M., Anderson C.J., Reichert D.E., Sun Y., Martell A.E., et al. Labeling and in vivo evaluation of novel copper(II) dioxotetraazamacrocyclic complexes. Nucl Med Biol 2000, 27:375-380.
    • (2000) Nucl Med Biol , vol.27 , pp. 375-380
    • Cutler, C.S.1    Wuest, M.2    Anderson, C.J.3    Reichert, D.E.4    Sun, Y.5    Martell, A.E.6
  • 70
    • 79551537113 scopus 로고    scopus 로고
    • Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours
    • Mansi R., Wang X., Forrer F., Waser B., Cescato R., Graham K., et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 2011, 38:97-107.
    • (2011) Eur J Nucl Med Mol Imaging , vol.38 , pp. 97-107
    • Mansi, R.1    Wang, X.2    Forrer, F.3    Waser, B.4    Cescato, R.5    Graham, K.6
  • 71
    • 0026334978 scopus 로고
    • Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells
    • Gladson C.L., Cheresh D.A. Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest 1991, 88:1924-1932.
    • (1991) J Clin Invest , vol.88 , pp. 1924-1932
    • Gladson, C.L.1    Cheresh, D.A.2
  • 72
  • 74
    • 33750823665 scopus 로고    scopus 로고
    • Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors
    • Ginj M., Zhang H., Waser B., Cescato R., Wild D., Wang X., et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A 2006, 103:16436-16441.
    • (2006) Proc Natl Acad Sci U S A , vol.103 , pp. 16436-16441
    • Ginj, M.1    Zhang, H.2    Waser, B.3    Cescato, R.4    Wild, D.5    Wang, X.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.